Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P D'Angelo

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Sarcoma|July 17, 2015
Corrigendum to "Sarcoma Immunotherapy: Past Approaches and Future Directions"S P D'Angelo, W D Tap, G K Schwartz, et al.
Sarcoma|April 30, 2014
Sarcoma immunotherapy: past approaches and future directionsS P D'Angelo, W D Tap, G K Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaM A Dickson, M R Mahoney, W D Tap, et al.
ESMO Open|May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 studyS P D'Angelo, C Lebbé, L Mortier, et al.
British Journal of Cancer|October 10, 2013
High-risk features in radiation-associated breast angiosarcomasS P D'Angelo, C R Antonescu, D Kuk, et al.
Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.
ESMO Open|October 29, 2021
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-upS P D'Angelo, S Bhatia, A S Brohl, et al.
ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.
ESMO Open|July 27, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcomaE Rosenbaum, K Seier, M Bradic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophagesC A Gomez-Roca, A Italiano, C Le Tourneau, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Sarcoma|July 17, 2015
Corrigendum to "Sarcoma Immunotherapy: Past Approaches and Future Directions"S P D'Angelo, W D Tap, G K Schwartz, et al.
Sarcoma|April 30, 2014
Sarcoma immunotherapy: past approaches and future directionsS P D'Angelo, W D Tap, G K Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaM A Dickson, M R Mahoney, W D Tap, et al.
ESMO Open|May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 studyS P D'Angelo, C Lebbé, L Mortier, et al.
British Journal of Cancer|October 10, 2013
High-risk features in radiation-associated breast angiosarcomasS P D'Angelo, C R Antonescu, D Kuk, et al.
Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.
ESMO Open|October 29, 2021
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-upS P D'Angelo, S Bhatia, A S Brohl, et al.
ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.
ESMO Open|July 27, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcomaE Rosenbaum, K Seier, M Bradic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2019
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophagesC A Gomez-Roca, A Italiano, C Le Tourneau, et al.
Pageof 1